Posters

Best of Posters Award

Abstract submission for poster and fast forward oral presentation are being accepted into the 2017 program.  Please submit your abstract via the online registration system

 

Best of Posters Award - 2016

The winner of the 2016 Best of Posters was Sharon Pattison of University of Otago for ‘Mismatch repair deficiency, inflammatory score and prognosis in gastric cancer’. The runner up was Melanie McCoy, St John of God Hospital Subiaco for ‘Immune biomarkers of response to chemoradiotherapy in locally advanced rectal cancer’.

The Best of Posters Award is proudly sponsored by Ipsen. The winner receives a $3,500 prize and certificate and runner up receives a $1,500 prize and certificate, both presented at the 18th AGITG Annual Scientific Meeting Dinner.

SetRatioSize190190 ipsen logo

 

18149 2428 resized
Dr Sharon Pattison is pictured receiving her award from AGITG Chair Professor Tim Price

18149 2432 resized
Dr Melanie McCoy is pictured receiving her award from AGITG Chair Professor Tim Price

Best of Posters Award - 2015

The Posters Session continued to grow in 2015. Dr Rebecca Tay from Eastern Health was awarded the Best of Posters for her poster entitled "Survival impact of adjuvant chemotherapy for resected early stage rectal adenocarcinoma". The AGITG is grateful for sponsorship from Ipsen for the Best of Posters.

posters website 300x210

Best of Posters Award - 2014

Congratulations go to the winners of the 2014 Posters Awards sponsored by Ipsen  

Dr Matthew Burge of Royal Brisbane Hospital won the Best Poster Award sponsored by Ipsen. Dr Burge’s poster was entitled: “A prospective, single institution study of the impact of Fluorodeoxyglucose (FDG) positron Emission Tomograpthy with concurrent non-contract CT scanning (PET/CT) on the management of operable Pancreatic, Ampullary or Distal Bile Duct cancer.” 

 

 

Dr David Chan of Royal North Shore Hospital was awarded runner up for his poster sponsored by Ipsen. Dr Chan’s poster was entitled: “The efficacy of EGFR inhibitors (I) in extended RAS wild-type and mutant settings in metastatic colorectal cancer (mCRC): A meta-analysis.”